• OnKure Therapeutics annual shareholder meeting set for June 3, 2026 in virtual format.
• Shareholders to vote on election of three Class II directors to serve through 2029.
• Meeting agenda includes ratification of KPMG as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
• Vote also scheduled on amended and restated 2024 Equity Incentive Plan, including a one-time increase of 3,231,638 shares and removal of 2,407,100-share annual cap in evergreen provision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-015903), on April 21, 2026, and is solely responsible for the information contained therein.